Yervoy Ploy Decoy? Pre-chemo Prostate Market Size in Dispute
By Randy Osborne
Thursday, September 12, 2013
As approved prostate cancer drugs duke it out in the prostate cancer space and scramble for pre-chemotherapy patients, Bristol-Myers Squibb Co.’s near-miss Phase III results with the anti-CTLA-4 drug Yervoy (ipilimumab) in advanced disease left some cause in the data for optimism that the melanoma therapy might fare better in a separate trial against earlier stages of the tumor.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.